Welcome to our dedicated page for NEVRO news (Ticker: $NVRO), a resource for investors and traders seeking the latest updates and insights on NEVRO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NEVRO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NEVRO's position in the market.
Nevro Corp. (NYSE: NVRO) will participate in the BofA Securities 2024 Healthcare Conference on May 14, 2024, presenting comprehensive pain treatment solutions. A webcast of the event will be available on the company's website.
Nevro Corp. reported its first-quarter 2024 financial results along with additional restructuring steps to boost profitability. The company raised its adjusted EBITDA guidance, reaffirmed revenue guidance for 2024, and promoted Christofer Christoforou to COO. Revenue grew to $101.9 million, with a net loss from operations of $35.8 million and adjusted EBITDA loss of $9.6 million. The company's improved gross margin, operating expenses, and cash position were highlighted. Full-year revenue guidance stands at $435 million to $445 million, with adjusted EBITDA guidance revised to a range of negative $5 million to positive $2 million for 2024.